Company intelligence / Profile preview

Senseonics

Germantown, Maryland, United Statessenseonics.com ↗

Ownership: Public · SENS
Development stage: Commercial

Overview

Senseonics has developed the first and only long-term implantable continuous glucose monitoring system. Its latest product, the Eversense 365 CGM system, received FDA approval in 2024 and offers up to one year of continuous glucose monitoring with minimal interruptions—significantly longer than traditional CGMs. The company’s patient base grew by over 56% in 2024 to approximately 6,000 global users. Early commercial results for the U.S. launch of Eversense 365 have been favorable[2][4][10].

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Physiological Monitoring

Drug pipeline

1 asset

Eversense 365

Commercial

Indications: Diabetes

Partnerships

Ascensia Diabetes Care (commercial partner for U.S. launch)Mercy Health (collaboration on remote patient monitoring/case study)

Financials

Market cap: $364.4M
Total revenue: $14.5M
Enterprise value: $283.6M

Beyond the preview

Go deeper on Senseonics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senseonics.

Explore the full profile